Internal Medicine, Hematology & Oncology · Washington, DC
NPI
1275896318
Since 2012
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
2041 Georgia Ave NW Fl 1
Washington, DC, 20060
Phone (202) 865-1002
Groups this clinician bills Medicare through
Medicare paid, 2024
$145K
1,827 services
Medicare patients, 2024
409
Average age 73
Drug cost, 2024
$2.9M
917 prescriptions
Company payments, 2025
$7,928
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ahmed M Ali was code 99232 (hospital e&m - subsequent), 1,043 times for 90 patients. In total Ahmed M Ali billed 1,827 services in 19 codes, and Medicare paid $145K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 1,043 | 90 | $66.77 | $70K |
| 99308 SNF E&M | Facility | 202 | 134 | $61.98 | $13K |
| 99305 SNF E&M | Facility | 146 | 145 | $111.02 | $16K |
| 99214 Office E&M - Established | Office | 121 | 59 | $96.22 | $12K |
| 99233 Hospital E&M - Subsequent | Facility | 113 | 46 | $100.51 | $11K |
| 99223 Hospital E&M - Initial | Facility | 54 | 52 | $146.93 | $7,934 |
| 99222 Hospital E&M - Initial | Facility | 36 | 34 | $111.72 | $4,022 |
| 99306 SNF E&M | Facility | 28 | 28 | $144.43 | $4,044 |
| 99213 Office E&M - Established | Office | 24 | 23 | $71.01 | $1,704 |
| 99204 Office E&M - New | Office | 21 | 21 | $140.82 | $2,957 |
| 99309 SNF E&M | Facility | 16 | 13 | $85.64 | $1,370 |
By year: 2022 $107K for 1,203 services; 2023 $116K for 1,246 services; 2024 $145K for 1,827 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ahmed M Ali prescribed most often to Medicare patients was Dexamethasone Sodium Phosphate, with 78 prescriptions and refills. In total Ahmed M Ali wrote 917 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dexamethasone Sodium Phosphate Generic | 78 | 78 | 13 | $256 |
| Diphenhydramine Hcl Generic | 76 | 76 | 15 | $249 |
| Granisetron Hcl Generic | 39 | 39 | Under 11 | $452 |
| Granisetron Hcl Granisetron Hcl/Pf | 37 | 37 | Under 11 | $730 |
| Anastrozole Generic | 34 | 98 | 14 | $623 |
| Eliquis Apixaban | 31 | 54 | Under 11 | $32K |
| Fluorouracil Generic | 30 | 30 | Under 11 | $1,966 |
| Magnesium Sulfate Generic | 29 | 29 | Under 11 | $120 |
| Perjeta Pertuzumab | 27 | 27 | Under 11 | $200K |
| Imatinib Mesylate Generic | 22 | 28 | Under 11 | $28K |
| Kanjinti Trastuzumab-Anns | 21 | 21 | Under 11 | $78K |
| Fosaprepitant Dimeglumine Generic | 21 | 21 | Under 11 | $2,008 |
| Famotidine Famotidine/Pf | 18 | 18 | Under 11 | $43.33 |
| Lupron Depot Leuprolide Acetate | 16 | 40 | Under 11 | $79K |
| Ondansetron Odt Ondansetron | 15 | 15 | Under 11 | $296 |
Brand drugs: 288 claims; generic drugs: 629 claims; opioid claims: 23.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ahmed M Ali $7,928 ($7,928 in general payments such as food, travel and fees) from 31 companies. The largest payer was Incyte Corporation with $4,119.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 8 | $4,119 |
| Janssen Biotech, Inc. JNJ | 22 | $672 |
| Novartis Pharmaceuticals Corporation NVS | 16 | $578 |
| Abbvie Inc. ABBV | 7 | $277 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $272 |
| Daiichi Sankyo Inc. 4568.T | 10 | $266 |
| Regeneron Healthcare Solutions, Inc. REGN | 9 | $245 |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $146 |
| Merck Sharp & Dohme LLC MRK | 6 | $131 |
| Syndax Pharmaceuticals, Inc. SNDX | 3 | $97.88 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.